Literature DB >> 1568224

Reactivation of insulin-like growth factor II during hepatocarcinogenesis in transgenic mice suggests a role in malignant growth.

P Schirmacher1, W A Held, D Yang, F V Chisari, Y Rustum, C E Rogler.   

Abstract

We have studied the expression of insulin-like growth factor II (IGF-II) during hepatocarcinogenesis in four independent transgenic mouse lines. In all four lines liver-directed transgene expression induces a stepwise and relatively synchronized tumorigenesis. IGF-II reexpression occurs in all four lines irrespective of the mechanism of tumor induction. Reexpression is chronologically associated with late progression steps toward hepatocellular carcinoma and correlated with the respective tumor progression rate in each line. IGF-II activation is focal and topographically associated with high replicative activity. IGF-II mRNAs in hepatocellular carcinomas show similarities to the expression pattern in fetal liver, and a M(r) 15,000 IGF-II polypeptide accumulates intracellularly in distinct cytoplasmic preferentially perinuclear compartments. These data indicate that IGF-II reexpression is a marker for progression to hepatocellular carcinoma and may contribute to hepatocarcinogenesis via an autocrine mechanism.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1568224

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  26 in total

1.  [Molecular mechanisms of progression in human hepatocarcinogenesis].

Authors:  K Breuhahn
Journal:  Pathologe       Date:  2010-10       Impact factor: 1.011

2.  Role of Raf Kinase Inhibitor Protein in Hepatocellular Carcinoma.

Authors:  Evan J Walker; Stephen A Rosenberg; Jack R Wands; Miran Kim
Journal:  For Immunopathol Dis Therap       Date:  2011

Review 3.  Targeting the insulin-like growth factor pathway in hepatocellular carcinoma.

Authors:  Mónica Enguita-Germán; Puri Fortes
Journal:  World J Hepatol       Date:  2014-10-27

Review 4.  The IGF axis and hepatocarcinogenesis.

Authors:  J G Scharf; F Dombrowski; G Ramadori
Journal:  Mol Pathol       Date:  2001-06

Review 5.  Autoantibodies to tumor-associated antigens as biomarkers in cancer immunodiagnosis.

Authors:  Weihong Liu; Bo Peng; Yumin Lu; Weijia Xu; Wei Qian; Jian-Ying Zhang
Journal:  Autoimmun Rev       Date:  2010-12-15       Impact factor: 9.754

6.  A methylated oligonucleotide inhibits IGF2 expression and enhances survival in a model of hepatocellular carcinoma.

Authors:  Xiaoming Yao; Ji-Fan Hu; Mark Daniels; Hadas Shiran; Xiangjun Zhou; Huifan Yan; Hongqi Lu; Zhilan Zeng; Qingxue Wang; Tao Li; Andrew R Hoffman
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

Review 7.  Epigenetic regulation of insulin-like growth factor axis in hepatocellular carcinoma.

Authors:  Hend Mohamed El Tayebi; Ahmed Ihab Abdelaziz
Journal:  World J Gastroenterol       Date:  2016-03-07       Impact factor: 5.742

Review 8.  Reactivation of the insulin-like growth factor-II signaling pathway in human hepatocellular carcinoma.

Authors:  Kai Breuhahn; Peter Schirmacher
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

9.  Apoptosis is induced by N-myc expression in hepatocytes, a frequent event in hepadnavirus oncogenesis, and is blocked by insulin-like growth factor II.

Authors:  K Ueda; D Ganem
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

10.  Transforming growth factor alpha dramatically enhances oncogene-induced carcinogenesis in transgenic mouse pancreas and liver.

Authors:  E P Sandgren; N C Luetteke; T H Qiu; R D Palmiter; R L Brinster; D C Lee
Journal:  Mol Cell Biol       Date:  1993-01       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.